Interleukin-6 (IL-6) is a cytokine that regulates the proliferation of some tumor cells including multiple myeloma (MM). Ectopic expression of fibroblast growth factor receptor 3 (FGFR3) associated with the chromosomal translocation, t(4;14)(p16.3;q32), is frequently found in MM, and therefore, has been implicated in the neoplastic transformation of this disease. Here, we show that IL-6 together with FGF enhanced proliferation of a myeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) and the FGFR3-transfected U266 myeloma cell line which ectopically expressed FGFR3 but responded to neither IL-6 nor FGF alone. In KMS-11, IL-6 activated signal transducer and activator of transcription 3 (STAT3) while FGF activated extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol (PI)-3 kinase. As both MEK inhibitors and a PI 3-kinase inhibitor abolished the effect of IL-6 and FGF, the activation of both the ERK1/2 and PI 3-kinase signaling cascades is essential for the proliferation of KMS-11 enhanced by IL-6 and FGF. Furthermore, the FGF-induced activation of ERK1/2 contributed to the serine phosphorylation of STAT3, suggesting that the signaling crosstalk between the cytokine receptor, IL-6 receptor a/gp130 and the growth factor receptor tyrosine kinase, FGFR3. These results indicate that FGFR3 plays a crucial role in the accelerated proliferation of MM carrying t(4;14)(p16.3;q32). Oncogene (2005) 24, 6328-6332.
Interleukin-6 (IL-6) is a cytokine that regulates the proliferation of some tumor cells including multiple myeloma (MM). Ectopic expression of fibroblast growth factor receptor 3 (FGFR3) associated with the chromosomal translocation, t(4;14)(p16.3;q32), is frequently found in MM, and therefore, has been implicated in the neoplastic transformation of this disease. Here, we show that IL-6 together with FGF enhanced proliferation of a myeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) and the FGFR3-transfected U266 myeloma cell line which ectopically expressed FGFR3 but responded to neither IL-6 nor FGF alone. In KMS-11, IL-6 activated signal transducer and activator of transcription 3 (STAT3) while FGF activated extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol (PI)-3 kinase. As both MEK inhibitors and a PI 3-kinase inhibitor abolished the effect of IL-6 and FGF, the activation of both the ERK1/2 and PI 3-kinase signaling cascades is essential for the proliferation of KMS-11 enhanced by IL-6 and FGF. Furthermore, the FGF-induced activation of ERK1/2 contributed to the serine phosphorylation of STAT3, suggesting that the signaling crosstalk between the cytokine receptor, IL-6 receptor a/gp130 and the growth factor receptor tyrosine kinase, FGFR3. These results indicate that FGFR3 plays a crucial role in the accelerated proliferation of MM carrying t(4;14)(p16.3;q32 ).
Most cases of myeloma exhibit Ig translocations involving numerous partner chromosomes, and may provide an early immortalizing event. Many genes are involved in these translocations that occur to the IgH S regions consistent with the phenotype of the disease, such as the expression of Ig isotypes other than IgM. Some partner genes appear to account for the majority of primary IgH (14q32) translocations, such as 4p16 (fibroblast growth factor receptor 3; FGFR3 and MM SET domain;MMSET/Wolf-Hirschhorn syndrome candidate 1; WHSC1) (Chesi et al., 1997 (Chesi et al., , 1998b Richelda et al., 1997; Avet-Loiseau et al., 1998; Malgeri et al., 2000) , 6p25 (interferon regulatory factor-4) (Iida et al., 1997) , 11q13 (cyclin D1) (Avet-Loiseau et al., 1998) , and 16q23 (c-maf) (Chesi et al., 1998a) . The chromosomal translocation, t(4;14)(p16;q32) results in ectopic expression of FGFR3 and IgH/MMSET hybrid transcripts in myeloma cells due to the effects of the 3 0 IgH enhancer (Chesi et al., 1997 (Chesi et al., , 1998b Richelda et al., 1997; Malgeri et al., 2000) .
FGFRs belong to the family of receptor tyrosine kinases (RTKs) capable of binding many related FGFs. FGFR3, one of four high-affinity FGFRs may promote or inhibit cell proliferation depending on cell types. Ligand binding promotes receptor homo-or hetrodimerization and consequent trans-phosphorylation of the receptor at several sites. These phosphorylated tyrosine residues form the binding sites for several src homology (SH) 2 domain-containing proteins that include the GTPase-activating protein of ras, phospholipase C-g, the src family protein tyrosine kinases (PTKs), phospatidylinositol (PI)-3 kinase, protein tyrosine phosphatases and adaptor proteins, such as Grb-2 and Shc. They lead to complex signaling pathways regulating cell proliferation, survival and differentiation (Klint and ClaessonWelsh, 1999) .
Janus kinase (JAK)-signal transducer and activator of transcription (STAT) is a key pathway that mediates cellular responses to a variety of cytokines because cytokine receptors lack intrinsic PTK activity, unlike the growth factor receptors. Cytokine binding to receptors activates JAKs, the receptor-associated PTKs that phosphorylate the target tyrosine residues on the cytoplasmic region of the receptors. STATs, the latent cytoplasmic transcription factors are recruited to the receptors through the binding of their SH-2 domain and subsequently phosphorylated by JAKs on specific tyrosine residues. STATs form homo-or heterodimers, translocate into the nucleus, bind to DNA, and regulate target gene expression (Hirano et al., 1997 (Hirano et al., , 2000 . Among seven members of STAT family, STAT3 is activated by a cytokine, interleukin-6 (IL-6) that binds to IL-6 receptor a chain (IL-6Ra)/gp130 complexes.
Cytokines and growth factors bind to their receptors on the cell surface and activate signal transduction pathways that frequently lead to cell proliferation and differentiation. Promotion of cell proliferation by cytokines or growth factors has been shown to correlate with the intracellular activation of common protein kinase cascades. Although IL-6 is a growth factor for myeloma cells (Kawano et al., 1988) , only CD45 þ immature tumor cells proliferate in response to IL-6 (Mahmoud et al., 1998; Fujii et al., 1999) , indicating that the activation of the other signaling molecules as well as STAT3 is required for the mitogenic signals in myeloma cells (Ishikawa et al., 2002) . To investigate the pathological relevance of ectopic expression of FGFR3 on myeloma cells, in this study, we mainly used a human Figure 1 Enhanced proliferation of KMS-11 by IL-6 together with FGF via distinct intracellular signaling pathways. Cell proliferation of a human myeloma cell line, KMS-11 (Namba et al., 1989) treated with or without IL-6 (R&D Systems) (a), bFGF/ FGF-2 (Genzyme Techne) (b) or aFGF/FGF-1 (Genzyme Techne) (c) at the indicated concentrations was analysed by BrdU incorporation (Amersham Pharmacia Biotech) as reported previously (Ishikawa et al., 2002) . Open and closed bars indicate cells treated without and with IL-6 (2 ng/ml), respectively (b, c). Values of BrdU incorporation are indicated by means and s.d. that were obtained from three independent experiments using triplicate samples (a, b, c) . BrdU incorporations of KMS-11 treated with FGF and IL-6 (*) but not with FGF and IL-6 alone were significantly different from that without stimulation indicated by Student's t-test (Po0.01) of statistical analysis (b, c). (d) Activation of STAT3, STAT1 and ERK1/2 in KMS-11 stimulated with either bFGF (100 ng/ ml) or IL-6 (2 ng/ml) for 0, 10, 30 or 90 min was determined by Western blot analysis (WB) using antibodies (Cell Signaling) that recognize the phosphorylated STAT3 at Tyr705 (STAT3-P), phosphorylated STAT1 at Tyr701 (STAT1-P) and phosphorylated ERK1/2 at Thr202/Tyr204 (ERK1/2-P). (e) The activation of STAT3, FGFR3 and PI 3-kinase in KMS-11 stimulated with bFGF, ILmyeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) (Chesi et al., 1997; Richelda et al., 1997) that expressed FGFR3 (Figures 1e and 3a) . Despite the expression of FGFR3 and IL-6Ra (data not shown) on KMS-11, its proliferation was not augmented by bFGF/FGF-2, aFGF/FGF-1 or IL-6 alone, whereas IL-6 together with FGF accelerated the proliferation (Figures 1a-c) , indicating the biological synergy between IL-6 and FGF in KMS-11.
Phosphorylation of a tyrosine residue at 705 in STAT3 was observed in KMS-11 in response to IL-6, whereas phosphorylation of STAT1, STAT5 and ERK1/2 was barely detectable (Figures 1d and e and data not shown). In contrast, bFGF induced the activation of ERK1/2 and PI 3-kinase but not of STAT3 (Figures 1d and e) . Although FGFR3 expressed in KMS-11 carries an amino acid substitution that results in a constitutive active RTK (Richelda et al., 1997) , this mutated FGFR3 was further phosphorylated by bFGF stimulation (Figure 1e) . Hence, the mutated FGFR3 in KMS-11 is still capable of responding to FGF.
Either a MEK1 inhibitor, PD98059 or PI 3-kinase inhibitor, Wortmannin at appropriate concentrations abolished the enhanced proliferation of KMS-11 by costimulation with IL-6 and bFGF (Figures 2a and b) . These reagents selectively blocked the phosphorylation of either ERK1/2 or PI 3-kinase (Figure 2c ). These results indicate that IL-6 and bFGF activate the distinct intracellular signaling pathways, and both the ERK1/2 and PI 3-kinase pathways activated by bFGF are necessary for the enhanced proliferation of KMS-11.
Figure 2 Both ERK1/2 and PI 3-kinase pathways were important for the enhanced proliferation of KMS-11 by IL-6 and bFGF and the FGF-induced ERK1/2 activation led to the serine phosphorylation of STAT3. Proliferation of KMS-11 was suppressed by the appropriate concentrations of a MEK1 inhibitor, PD98059 (Cell Signaling) (a) or PI 3-kinase inhibitor, Wortmannin (Sigma) (b). Values of BrdU incorporation are indicated by means and s.d. that were obtained from three independent experiments using triplicate samples (a, b). BrdU incorporations of KMS-11 stimulated with bFGF and IL-6 were significantly different (*) from no stimulation without inhibitors (Po0.01), whereas those were similar with appropriate concentrations of inhibitors (a, b). (c) KMS-11 pretreated without or with PD98059 (10 mM) or Wortmannin (100 nM) for 30 min was stimulated without or with bFGF and IL-6 for 10 min, followed by Western blot or IP-Western analysis using indicated antibodies. (d) KMS-11 pretreated with either control DMSO or a MEK1/2 inhibitor, U0126 (10 mM, Cell Signaling) for 30 min was stimulated without or with bFGF and IL-6 for 10 min followed by Western blot analysis using phospho-STAT3 (Tyr705), phospho-STAT3 (Ser727) or STAT3 antibodies (Cell Signaling). Histograms were shown as values of STAT3 phosphorylation relative to without stimuli and inhibitor (Fold phosphorylation). STAT3 phosphorylation was quantified as densities of bands by Scion image software (Scion, Frederick, MA, USA)
The IL-6-induced STAT3 activation is also required for the enhanced proliferation of KMS-11 because FGF alone failed to enhance the proliferation of KMS-11 (Figures 1b and c) . In addition to the tyrosine phosphorylation, phosphorylation of a specific serine residue at 727 within transcriptional activation domain of STAT3 is necessary for maximal transcriptional activity and increases the magnitude of its target gene expression (Wen et al., 1995; Zhang et al., 1995) . In KMS-11, bFGF but not IL-6 stimulation induced the phosphorylation of Ser727 in STAT3, and a selective MEK1/2 inhibitor, U0126 abolished the serine-but not tyrosine-phosphorylation of STAT3 in response to bFGF and IL-6 stimulations ( Figure 2d and data not shown), supporting the notion that two independent signaling pathways converge on STAT3 to regulate its function in the cell. Although the identity of the serine/threonine kinases that phosphorylate the conserved carboxy terminus serine residue in STAT family members has remained elusive, our results imply that the bFGF-induced activation of ERK1/2 pathway is involved in the phosphorylation of the critical serine residue of STAT3 (Chung et al., 1997) . Furthermore, the bFGF-induced activation of ERK1/2 seemed to enhance the transcriptional activity of STAT3 in luciferase assay (data not shown). Costimulation of KMS-11 with bFGF and IL-6 led to marked expression of STAT3 target genes, such as c-myc (Kiuchi et al., 1999) and bcl-2 (Fukada et al., 1996) (data not shown), further suggesting the relevance of STAT3 phosphorylated at both Tyr705 and Ser727 for the full activation as a transcription factor.
To confirm the synergy between IL-6 and bFGF for proliferation of myeloma cells ectopically expressing FGFR3, we have established the FGFR3-transfectants of other myeloma cell line U266, U266 FGFR3 (u) and U266 FGFR3 (1). Both transfectants expressed the transgene-derived functional FGFR3 proteins (Figure 3a ) because ERK1/2 were phosphorylated in the FGFR3-transfected U266 but not in mock in response to bFGF (Figure 3b ). IL-6 together with bFGF enhanced the proliferation of the FGFR3-transfected U266 but not mock whereas neither IL-6 nor bFGF alone influenced their proliferation (Figure 3c) , consistent with the results obtained from KMS-11 (Figures 1a and b) . In addition, the expression of FGFR3 may render the IL-6-responsive CD45 þ myeloma cells sensitive to IL-6 for cell growth because the suboptimal doses of IL-6 enhanced the proliferation of the FGFR3-transfected CD45 þ U266 (data not shown). This may be physiologically important because unlike in vitro experiments, the amounts of soluble factors, such as IL-6 and FGF, must be limited in vivo.
Ig translocations involve a plethora of different molecules that influence many different pathways. It has been reported that ectopic expression of FGFR3 contributes to growth promotion and anti-apoptosis (Plowright et al., 2000) and acts as a transforming oncogene (Chesi et al., 2001 ) of myeloma cells carrying t(4;14)(p16.3;q32). In this study, we show for the first time the proliferative synergy between IL-6 and FGF, and explore the signaling events underlying the (Otsuki et al., 1998) were shown by Western blot analysis. The human fgfr3 cDNA (Keegan et al., 1991) was synthesized with RT-PCR using polyA þ RNA from KMS-11. First strand DNA was synthesized with fgfr3-RT, and either fgfr3-U or fgfr3-1 as sense primers and fgfr3-D as an antisense primer amplified the full-length fgfr3 cDNA. After confirming the nucleotide sequence of the fragments, they were transferred into the retroviral vector pRep (pMxpuro, Onishi et al., 1998) followed by retrovirus infection into U266 myeloma cell line as reported previously (Abroun et al., 2004) . Signaling cross-talk of IL-6 and FGFR3 in myelomas H Ishikawa et al important biologic interaction between IL-6 and FGF in t(4;14)(p16.3;q32) MM. In agreement with the synergistic effect of cytokines and growth factors on cells through complementary signaling pathways (Duarte and Frank, 2000) , here, we provide a novel mechanism of MM growth mediated by signaling cross-talk between RTK and cytokine receptor.
